Adriamycin動注療法が著効を呈した進行腎細胞癌

概要

論文の詳細を見る
There are many cases of advanced renal cell carcinoma refractory to chemotherapy with cytotoxic agents and/or hormonal drugs. Adriamycin, an etnthracycline antitumor agent, has wide spectrum of antitumor activities. After injected, adriamycin disappears from blood in a short time and it is absorbed and accumulated into organs. According to these characteristics, it is suggested that adriamycin is one of the most suitable drug for intraarterial infusion therapy. This paper reports a case of renal cell carcinoma refractory to the chemotherapy with Provera, mitomycin C, S-fluorouracil and cyclophosphamide in combination, who was treated with adriamycin (total dose of400 mg) by intraarterial infusion. The good response to adriamycin was demonstrated in both primary and metastatic tumors, but the patient died due to renal insufficiency after 3 months remission. In the postmortem study, it was found that the renal tumor was replaced mostly with scar tissue, in which a few non-viable tumor cells were found in making small nests. Since degenerated renal nephrons due to adriamycin was not found, it was thought that renal dysfunction was caused by a large scared tumor mass pressing the renal collecting systems and blood supplies.
泌尿器科紀要刊行会の論文